Cancer genomic profiling can be challenging for patients with limited tissue sample, especially in cancer types such as lung cancer where small biopsy samples coupled with low tumor cellularity are the norm. By performing macrodissection and utilizing our expertise in handling FFPE samples, ACT Genomics is able to offer high success rate in FFPE and provide more comprehensive information on copy number variation (CNV) and mutations, with a small amount of specimens.
ACTOnco®+ comprehensive genomic profiling, ACT Genomics’ flagship panel, covers tumor mutational burden (TMB), microsatellite instability (MSI) status and immune-related genes to provide a more accurate prediction of ICI responses.
For every report, ACT Genomics provides one-on-one report consultation for ordering physician. Our user-friendly reports offer clinically significant insights through logically-organized content and intuitive graphics.
Identify More Evidence-Based Treatment Options
ACT Genomics panels are designed to support physicians with evidence-based and actionable insights to answer clinical challenges in cancer management. Identifying the genetic alterations harbored in the patient’s tumor and understanding how they affect cancer-related cell signaling pathways to drive tumor growth are the keys to finding suitable treatment strategies for each patient.
Comprehensive Genomic Profiling
BRCA1/2&DNA Repair Gene Testing
Real-Time Monitoring with Liquid Biopsy
ACTMonitor® uses circulating tumor DNA (ctDNA) to provide an early detection of cancer recurrence and drug resistance. ctDNA consists of fragments of DNA released from necrotic or apoptotic tumor cells into the blood stream. ACTMonitor® detects the occurrence of variants that would lead to drug sensitivity or resistance, allowing assessment of treatment responses before changes can be observed by protein markers and in radioimages.
Cancer Monitoring
Real-time monitoring through blood specimen
Detects drug resistance
Assesses treatment responses
Identify High Risk Groups for Hereditary Cancer
Approximately 5-10% of cancers are caused by germline mutations. In addition to the well-characterized BRCA1/2, mutations in many other genes also cause a higher lifetime risk of cancer, up to 10-90 times higher than for someone without a mutation.
ACTRisk™ is a genetic test that analyzes 32 genes strongly associated with common hereditary cancers. It provides important genetic information that helps physicians and genetic counselors to precisely evaluate cancer risk and discuss risk management options with clients.
Genetic alterations associated with immunotherapy response in advanced NSCLC 2019-09-23
The results of a phase III study (MYSTIC) showed that ARID1A mutation were associated with clinical benefits in patients received durvalumab plus tremelimumab combination therapy
Dabrafenib and trametinib shows promising activity in pre-treated BRAF V600E/K mutated tumors 2019-09-23
In NCI-MATCH trial (Arm H), dabrafenib plus trametinib showed antitumor activity in patients with pre-treated tumors harboring BRAF V600E/K mutations (except melanoma, thyroid cancer, and colorectal cancer).
Molecular-matched therapy improves overall survival in pancreatic cancer 2019-09-23
The results from the Know Your Tumor (KYT) presented at 2019 ASCO demonstrated a significant improvement in overall survival in pancreatic cancer patients with highly actionable alterations that received matched targeted therapy versus those only received
BLU-667 demonstrates the antitumor activity in RET fusion-positive NSCLC and other cancers 2019-08-23
RET rearrangements have been found to promote cell proliferation in cancer, and a phase I study showed BLU-667 has antitumor activity in patients with RET fusion-positive tumor.
TAK-788 Shows Clinical Benefit in NSCLC Patients with EGFR Exon 20 Insertions 2019-08-23
No currently approved drug can target the EGFR exon 20 insertions in NSCLC, and TAK-788 is a potential treatment for these type of patients.
Olaparib shows efficacy in castration-resistant prostate cancer with defects in DNA-repair genes. 2019-08-23
The PARP inhibitor olaparib demonstrates antitumor activity in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair gene defects.
Step 1.
We are highly experienced and possess professional high standard procedures in the challenging process of retrieving DNA from FFPE samples for sequencing. Our scientists have optimized the methodology to consistently achieve successful sequencing with highly accurate results. In addition to FFPE samples, our platform also works with core needle biopsies, pleural effusion, ascites, blood samples, and buccal swaps.
Step 2.
ACT Genomics has established a state-of-the-art next generation sequencing (NGS) platform. Sequencing is performed on Ion Personal Genome Machines, Ion Proton sequencers and Illumina MiSeq; ACT Genomics is an Ion Torrent™ Certified Service Provider.
Step 3.
ACT Genomics integrates advanced annotation and visualization tools, coupled with public and proprietary databases to deliver comprehensive and comprehensible reports.
Step 4.
With accurate genomic profiling, visualizing genes with alterations in known cancer pathways and providing potential matching cancer targeted treatments from FDA and National Comprehensive Cancer Network (NCCN) guidelines, mutated sub-network in known pathways, as well as references, ACT Genomics aims to deliver a concise, reliable and actionable meaningful clinical report.
